Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127922 | 0.80 | HTR2B (0.42) | ALDH1A1HPGDRXFP1 | |
| SCHEMBL5119745 | 0.76 | AHR (0.39) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL7699644 | 0.73 | ALDH1A1 (0.56) | RECQLALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL22249795 | 0.70 | HPGD (0.43) | RECQLALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8171245 | 0.69 | CYP19A1 (0.38) | LMNAMAPK10 | |
| SCHEMBL5988696 | 0.68 | HPGD (0.65) | RECQLALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4279053 | 0.68 | RECQL (0.60) | RECQLALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5329513 | 0.68 | ALDH1A1 (0.44) | RECQLALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5128456 | 0.67 | IDO1 (0.44) | SMN1; SMN2HSD17B10 | |
| SCHEMBL19418726 | 0.67 | CYP11B1 (0.52) | RECQLALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224183-B1 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | claimed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | claimed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1224183-B1 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | disclosed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | NHERF1, SLC9A3, SLC9A1 | RECQL 428/4885ALDH1A1 1856/4885KDM4E 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.